Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now small index

Intraductal Papillary Mucinous Neoplasm clinical trials

2 of 5 indexed Intraductal Papillary Mucinous Neoplasm trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Intraductal Papillary Mucinous Neoplasm: 5 US clinical trials tracked, 2 recruiting.

Intraductal Papillary Mucinous Neoplasm is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. The most active sponsor is Boston Scientific Corporation, running 1 of these trials.

Enrollment posture brief

Registry condition intraductal-papillary-mucinous-neoplasm

OPEN 2 | RECR 40% | LATE 0 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Intraductal Papillary Mu (th…40%
Open-enrollment share among volume-matched conditions near Intraductal Papillary Mucinous Neoplasm

Intraductal Papillary Mucinous Neoplasm lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Intraductal Papillary Mucinous Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Intraductal Papillary Mucinous Neoplasm is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Intraductal Papillary Mucinous Neoplasm research.

    Boston Scientific Corporation accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Intraductal Papillary Mucinous Neoplasm enrolment sits around 2,000 participants.

    Median target enrolment is 2,000 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Intraductal Papillary Mucinous Neoplasm research leans observational.

    1 interventional and 4 observational studies make up this index (20% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Intraductal Papillary Mucinous Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

SpyGlass Device
1 trials
Nutrition (N) Behavioral
1 trials
Physical Activity (PA) Behavioral
1 trials
Survey Other
1 trials

US sites by state

Facility locations filed on Intraductal Papillary Mucinous Neoplasm trials. A trial with sites in several states counts in each.

Maryland 3 trials
Texas 1 trials
New York 1 trials
North Carolina 1 trials
Minnesota 1 trials
Massachusetts 1 trials
Indiana 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Intraductal Papillary Mucinous Neoplasm page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Intraductal Papillary Mucinous Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Boston Scientific Corporation sponsors the most Intraductal Papillary Mucinous Neoplasm trials on record, review their full trial history before evaluating a specific study. See Boston Scientific Corporation's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Intraductal Papillary Mucinous Neoplasm condition card totals 5 registered trials; most-linked intervention SpyGlass; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.